AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11773150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 60 microg/kg
Number of subjects: 36
Study 11773150 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (control group, n = 8)
Number of subjects: 36
Study 11773150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 20, 60, or 100 microg/kg
Number of subjects: 36
Study 9436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (0.4 mL daily)
Number of subjects: 91
Study 9436336 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (15 mL daily)
Number of subjects: 91
Study 9436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 91
Study 9436336 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 91
Study 7662751 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 72
Study 7662751 — intervention group
Group type: COMPARATOR
Intervention: Practice (no feedback)
Number of subjects: 72
Study 7662751 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent EMG feedback
Number of subjects: 72
Study 7662751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low awareness biofeedback group
Number of subjects: 72
Study 7662751 — intervention group
Group type: EXPERIMENTAL
Intervention: High awareness biofeedback group
Number of subjects: 72
Study 2520620 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily (b.d.)
Number of subjects: 10
Study 2520620 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine four times daily (q.d.s.)
Number of subjects: 10
Study 2520620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine eye-drops (0.2%)
Number of subjects: 12
Study 145354 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (5%)
Number of subjects: 12
Study 145354 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine (5%) together with tropicamide (0.5%)
Number of subjects: 12
Study 31633185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 72
Study 31633185 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 72
Study 30519766 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80
Study 30519766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27798417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 3620
Study 27798417 — intervention group
Group type: COMPARATOR
Intervention: Other Angiotensin-converting enzyme inhibitors
Number of subjects: 3620
Study 25581921 — intervention group
Group type: EXPERIMENTAL
Intervention: Web access to PAP usage data
Number of subjects: 138
Study 25581921 — intervention group
Group type: EXPERIMENTAL
Intervention: Web access to PAP usage data with financial incentive
Number of subjects: 138
Study 25581921 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 25581921 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Outcomes of Sleep Questionnaire
Number of subjects: 138
Study 23933232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling the skin to 20 C
Number of subjects: 12
Study 23933232 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 12
Study 23933232 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch application (all sites)
Number of subjects: 12
Study 20950961 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D-CT scanning techniques
Number of subjects: 9
Study 19038356 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 600 microg
Number of subjects: 30
Study 19038356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 120 microg
Number of subjects: 30
Study 19038356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16473753 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic acupuncture
Number of subjects: 62
Study 16473753 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic acupuncture plus auriculotherapy
Number of subjects: 62
Study 15663229 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 60
Study 15663229 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 60
Study 15663229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16886330 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparasitic treatment with metronidazole
Number of subjects: 22
Study 16886330 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22
Study 9165632 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine and traditional neuroleptics
Number of subjects: 0
Study 8384097 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 8384097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3706817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 7
Study 3706817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 7
Study 31124619 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0
Study 31124619 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 0
Study 29716637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subdissociative dose)
Number of subjects: 0
Study 29716637 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 26877169 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 123
Study 25037206 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50-100 mg/d (flexible dosing)
Number of subjects: 50
Study 25037206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22700860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks)
Number of subjects: 58
Study 22700860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22700860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 58
Study 20020107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per thousand alcohol administration
Number of subjects: 22
Study 20020107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17627745 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone treatment (300 mcg/day)
Number of subjects: 132
Study 17627745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 15369884 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional education (MPE)
Number of subjects: 121
Study 15369884 — intervention group
Group type: COMPARATOR
Intervention: Uni-professional groups
Number of subjects: 121
Study 11464446 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 826
Study 11464446 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 826
Study 9755360 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg orally)
Number of subjects: 7
Study 9755360 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 7
Study 7735153 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous contralateral sound stimulation
Number of subjects: 0
Study 7735153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions affecting the auditory afferent pathway
Number of subjects: 0
Study 3293092 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.2 mg IV)
Number of subjects: 44
Study 3293092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 4917915 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent inactivated vaccine of the Hong Kong strain of influenza A virus
Number of subjects: 1601
Study 4917915 — intervention group
Group type: COMPARATOR
Intervention: Polyvalent vaccine containing only pre‐1968 Asian viruses
Number of subjects: 1601
Study 4917915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray of the Hong Kong vaccine in addition to injected Asian vaccine
Number of subjects: 1601
Study 29410606 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lemon verbena extract once daily
Number of subjects: 44
Study 29410606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28145421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the Nordic Nutrition Recommendations (NNR) as measured by the Healthy Food Intake Index (HFII)
Number of subjects: 137
Study 28145421 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the NNR as measured by HFII
Number of subjects: 137
Study 26429636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CT screening
Number of subjects: 1329506
Study 23633626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Tissue Management (NTM) - brief education, manual therapy, and nerve gliding exercises for 4 treatments over 2 weeks
Number of subjects: 60
Study 23633626 — intervention group
Group type: COMPARATOR
Intervention: Advice to remain active (Control) - instruction to continue usual activities
Number of subjects: 60
Study 21245962 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 25
Study 21245962 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive risk factors (number of children born)
Number of subjects: 14661
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 14661
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-European ancestry
Number of subjects: 14661
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia/eclampsia
Number of subjects: 14661
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular periods
Number of subjects: 14661
Study 18458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 14661
Study 17313010 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Quchi (LI 11) and Hegu (LI 4) on the affected side after raising handclasp of Bobath
Number of subjects: 0
Study 17313010 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising handclasp of Bobath after electroacupuncture at Quchi (LI 11) and Hegu (LI 4)
Number of subjects: 0
Study 17313010 — intervention group
Group type: COMPARATOR
Intervention: Simple electroacupuncture or exercise therapy
Number of subjects: 0
Study 12650654 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling breathing
Number of subjects: 24
Study 12650654 — intervention group
Group type: EXPERIMENTAL
Intervention: Music audiotape
Number of subjects: 24
Study 12650654 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 11052431 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (Oxygen group)
Number of subjects: 30
Study 11052431 — intervention group
Group type: COMPARATOR
Intervention: 50% oxygen (Air group)
Number of subjects: 30
Study 9471669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime for 12 months
Number of subjects: 50
Study 9471669 — intervention group
Group type: COMPARATOR
Intervention: Placebo at bedtime for 12 months
Number of subjects: 50
Study 7920941 — intervention group
Group type: EXPERIMENTAL
Intervention: NO and Pg E1 combination
Number of subjects: 50
Study 7920941 — intervention group
Group type: COMPARATOR
Intervention: NO alone
Number of subjects: 50
Study 7920941 — intervention group
Group type: COMPARATOR
Intervention: Pg E1 alone
Number of subjects: 50
Study 3883738 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg orally (single dose)
Number of subjects: 10
Study 3883738 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg orally (long-term treatment, 3 times daily for 3 weeks)
Number of subjects: 10
Study 3883738 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with digitalis and diuretics (Control)
Number of subjects: 10
Study 29611171 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 60
Study 29611171 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 30184031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (50,000 U)
Number of subjects: 328
Study 30184031 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplementation (control)
Number of subjects: 328
Study 27477798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography
Number of subjects: 120
Study 27477798 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative conventional X-ray cholangiography (reference group)
Number of subjects: 120
Study 25420552 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate plus sucrose (0.4 g · kg(‐1) each)
Number of subjects: 0
Study 25420552 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric sucrose control (0.8 g · kg(‐1))
Number of subjects: 0
Study 25420552 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with immediate ingestion
Number of subjects: 0
Study 25420552 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and sucrose (0.4 + 0.4 g · kg(‐1) · h(‐1)) with overnight ingestion
Number of subjects: 0
Study 22905153 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (stress task)
Number of subjects: 81
Study 22905153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress task)
Number of subjects: 81
Study 21078735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 141
Study 21078735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 18197744 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group visits (GVs)
Number of subjects: 186
Study 18197744 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 15673380 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daytime SD12 (Poincare dimension)
Number of subjects: 740
Study 15673380 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased 24-hour SD12 (Poincare dimension)
Number of subjects: 740
Study 15673380 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased ln ULF (ultra low frequency)
Number of subjects: 740
Study 15673380 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior MI
Number of subjects: 740
Study 15673380 — intervention group
Group type: EXPERIMENTAL
Intervention: History of congestive heart failure
Number of subjects: 740
Study 12917847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (balance and resistance training)
Number of subjects: 15
Study 12917847 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance group (balance training only)
Number of subjects: 15
Study 10624069 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms/kg bolus followed by infusion of up to 100 micrograms/kg/min)
Number of subjects: 30
Study 10624069 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study 8943670 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 139
Study 8943670 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 139
Study 8943670 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate and Tamoxifen
Number of subjects: 139
Study 1681268 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (52 megaunits for an average of 30 days)
Number of subjects: 25
Study 1681268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study 6378307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenclofenac
Number of subjects: 63
Study 6378307 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 63
Study 30476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1157
Study 30476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1157
Study 30476584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 30476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib overall cohort (average dose 10 mg twice daily)
Number of subjects: 1157
Study 30476584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib overall cohort
Number of subjects: 1157
Study 28032435 — intervention group
Group type: EXPERIMENTAL
Intervention: Short rest (30 s) combined with low load (20 RM) (SL)
Number of subjects: 20
Study 28032435 — intervention group
Group type: COMPARATOR
Intervention: Long rest (3 min) and high load (8 RM) (LH)
Number of subjects: 20
Study 26598418 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam during the procedure
Number of subjects: 150
Study 26598418 — intervention group
Group type: COMPARATOR
Intervention: No sedative treatment
Number of subjects: 150
Study 25176289 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus medical therapy
Number of subjects: 1220
Study 25176289 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1220
Study 25176289 — intervention group
Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 1220
Study 22484664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrite therapy
Number of subjects: 0
Study 22484664 — intervention group
Group type: COMPARATOR
Intervention: Low dose nitrite infusion
Number of subjects: 0
Study 20204967 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 0
Study 20204967 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0
Study 17659837 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐705498 (400mg)
Number of subjects: 19
Study 17659837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17822338 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting methylphenidate (Medikinet retard, MPH-MR)
Number of subjects: 85
Study 17822338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 14764790 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 10835790 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline development process
Number of subjects: 48
Study 10835790 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified barriers to clinical change
Number of subjects: 48
Study 9105648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 19
Study 9105648 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 19
Study 8241229 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort, 1.5 mg/kg/day, tapered to 0.25 mg/kg/day after 2-3 weeks
Number of subjects: 31
Study 8241229 — intervention group
Group type: COMPARATOR
Intervention: Prednisone, 1 mg/kg/day, tapered to 0.15 mg/kg/day after 2-3 weeks
Number of subjects: 31
Study 3516202 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 205
Study 3516202 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 205
Study 31259628 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced in-treatment systolic blood pressure (SBP)
Number of subjects: 1320
Study 31259628 — intervention group
Group type: COMPARATOR
Intervention: Non-ISH patients
Number of subjects: 1320
Study 31259628 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in in-treatment SBP
Number of subjects: 1320
Study 31259628 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of SBP reduction and AF prevention
Number of subjects: 1320
Study 29059313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 23
Study 29059313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (85% SpO2)
Number of subjects: 23
Study 29059313 — intervention group
Group type: COMPARATOR
Intervention: Hypercapnia
Number of subjects: 23
Study 26063441 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blocker) administered in a double-blind, placebo-controlled study
Number of subjects: 0
Study 26063441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 23719216 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise programme
Number of subjects: 68
Study 23719216 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 68
Study 22114276 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-induced motion parallax with binocular viewing conditions
Number of subjects: 0
Study 22114276 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-induced motion parallax with monocular viewing conditions
Number of subjects: 0
Study 18594955 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing children answering yes‐no questions about a transgression (Experiments 1 and 5)
Number of subjects: 0
Study 18594955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating adults who provided truthful or fabricated accounts (Experiment 2)
Number of subjects: 0
Study 18594955 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of deceivers (children versus adults) and interviews (closed‐ended questions versus extended accounts) (Experiment 3)
Number of subjects: 0
Study 18594955 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of deceptive scenario (naturalistic vs. experimentally‐manipulated) (Experiment 4)
Number of subjects: 0
Study 16523267 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice gel (control + 2.5% liquorice extract)
Number of subjects: 16
Study 16523267 — intervention group
Group type: COMPARATOR
Intervention: Control gel (8% acid‐hydrolyzed corn starch, 25% maltitol syrup, water)
Number of subjects: 16
Study 16523267 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice gel
Number of subjects: 16